Human brain tumor imaging with a protein-binding MR contrast agent: Initial experience

European Radiology

Volumn 20, Issue 1, 2010, Pages 218-226

  Essig, Marco ^a   Rohrer, Martin ^b   Giesel, Frederik ^a   Tüttenberg, Jochen ^c   Weber, Marc André ^a   Michaely, Hendrik ^c   Gerigk, Lars ^a   Voth, Matthias ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Department of Mathematics Physics and Chemistry   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Blood pool; Brain tumor; Contrast agents; Protein binding

Indexed keywords

GADOFOSVESET; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG DOSE COMPARISON; EPENDYMOMA; FEMALE; GLIOBLASTOMA; HUMAN; IMAGE DISPLAY; IMAGE QUALITY; MALE; MENINGIOMA; NEURINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BINDING; RATING SCALE; VASODILATATION;

ADULT; AGED; BLOOD PROTEINS; BRAIN; BRAIN NEOPLASMS; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GADOLINIUM; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 76949105672     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-009-1530-3     Document Type: Article

References (27)

1. M Brant-Zawadski D Norman TH Newton 1984 Magnetic resonance imaging of the brain: the optimal screening technique Radiology 152 71 77
2. TN Byrne 1994 Imaging of gliomas Sem Oncol 21 162 171 1:STN:280:DyaK2c3gsVKrsg%3D%3D
3. PM Black 1991 Brain tumor. Part 2 N Engl J Med 324 1555 1564 1:STN:280:DyaK3M3is1CrsQ%3D%3D 2027359
4. JP Stack NM Antoun JP Jenkins R Metcalfe I Isherwood 1988 Gadolinium-DTPA as a contrast agent in magnetic resonance imaging of the brain Neuroradiology 30 145 154 10.1007/BF00395616 1:STN:280:DyaL1c3mtFKrsQ%3D%3D 3386808 (Pubitemid 18109033)
5. JR Hesselink ME Healy GA Press FJ Brahme 1988 Benefits of Gd-DTPA for MR imaging of intracranial abnormalities J Comput Assist Tomogr 12 266 274 10.1097/00004728-198803000-00015 1:STN:280:DyaL1c7ntVajtA%3D%3D 3351041
6. AD Elster DM Moody MR Ball DW Laster 1989 Is Gd-DTPA required for routine cranial MR imaging Radiology 173 231 238 1:STN:280:DyaL1MzoslKmtA%3D%3D 2781014
7. G Sze E Milano C Johnson L Heier 1990 Detection of brain metastases: comparison of contrastenhanced MR with unenhanced MR and enhanced CT AJNR Am J Neuroradiol 11 785 791 1:STN:280:DyaK3czhtlGqtA%3D%3D 2114769
8. EA Neuwelt 2004 Mechanisms of disease: the blood-brain barrier Neurosurgery 54 131 140 10.1227/01.NEU.0000097715.11966.8E 14683550
9. J Bart HJ Groen NH Hendrikse, et al. 2000 The blood-brain barrier and oncology: new insights into function and modulation Cancer Treat Rev 26 449 462 10.1053/ctrv.2000.0194 1:STN:280:DC%2BD3M7gvVKiug%3D%3D 11139374 (Pubitemid 32094862)
10. K Nikolaou H Kramer C Grosse D Clevert, et al. 2006 High-spatial- resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience Radiology 241 861 872 10.1148/radiol. 2413060053 17032914 (Pubitemid 46190554)
11. VM Runge 2001 A review of contrast media research in 1999-2000 Invest Radiol 36 123 130 10.1097/00004424-200102000-00010 1:STN:280: DC%2BD3M3hsVSktQ%3D%3D 11224761 (Pubitemid 32147861)
12. C Brekenfeld E Foert W Hundt, et al. 2001 Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T Invest Radiol 36 266 275 10.1097/00004424-200105000-00004 1:STN:280:DC%2BD3MnjsV2rtw%3D%3D 11323514 (Pubitemid 32436607)
13. A Huppertz M Rohrer 2004 Gadobutrol, a highly concentrated MR-imaging contrast agent: its physicochemical characteristics and the basis for its use in contrast-enhanced MR angiography and perfusion imaging Eur Radiol Suppl 14 [Suppl 5] M12 M18
14. M Essig MA Weber H von Tengg-Kobligk MV Knopp WT Yuh FL Giesel 2006 Contrast-enhanced magnetic resonance imaging of central nervous tumors: agents, mechanisms and applications Top Magn Reson Imaging 17 89 106 10.1097/01.rmr.0000245464.36148.dc 17198225 (Pubitemid 46050572)
15. M Hartmann AJ Wiethoff HR Hentrich M Rohrer 2006 Initial imaging recommendations for Vasovist angiography Eur Radiol Suppl 16 [Suppl 2] B15 B23 10.1007/s10406-006-0163-8
16. TM Grist FR Korosec DC Peters, et al. 1998 Steady-state and dynamic MR angiography with MS-325: initial experience in humans Radiology 207 539 544 1:STN:280:DyaK1c3jvVelug%3D%3D 9577507
17. P Perreault MA Edelmann RA Baum, et al. 2003 MR angiography with gadofosveset trisodium for peripheral artery disease: phase II trial Radiology 229 811 820 10.1148/radiol.2293021180 14593194 (Pubitemid 37467588)
18. M Goyen M Edelmann P Perreault, et al. 2005 MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325 Radiology 236 825 833 10.1148/radiol.2363040577 16020554 (Pubitemid 41170843)
19. HB Eldredge M Spiller JM Chasse MT Greeenwood P Caravan 2006 Species dependence on plasma protein binding and relaxivityof the gadolinium-based MRI contrast agent MS-325 Invest Radiol 41 229 243 10.1097/01.rli.0000199293.86956. 48 1:CAS:528:DC%2BD28XhsVKqtr0%3D 16481905 (Pubitemid 44406183)
20. K Adzamli DA Yablonski MR Chicoine, et al. 2003 Albumin-binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model Magn Reson Med 49 586 590 10.1002/mrm.10382 12594765 (Pubitemid 36262830)
21. A Farooki V Narra J Brown 2004 Gadofosveset EPIX/Schering Curr Opin Investig Drugs 5 967 976 1:CAS:528:DC%2BD2cXpsVSis7g%3D 15503653
22. M Rohrer H Bauer J Mintorovitch M Requardt HJ Weinmann 2005 Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths Invest Radiol 40 715 724 10.1097/01.rli.0000184756.66360.d3 16230904 (Pubitemid 41546838)
23. KR Maravilla JA Maldjian IM Schmalfuss MJ Kuhn BC Bowen FJ Wippold 2nd VM Runge MV Knopp S Kremer LJ Wolansky N Anzalone M Essig L Gustafsson 2006 Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents Radiology 240 389 400 10.1148/radiol.2402051266 16801373 (Pubitemid 44098634)
24. SE Cowper PJ Boyer 2006 Nephrogenic systemic fibrosis: an update Curr Rheumatol Rep 8 151 157 10.1007/s11926-006-0056-9 16569375 (Pubitemid 44623984)
25. T Grobner 2006 Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis Nephrol Dial Transplant 21 1104 1108 10.1093/ndt/gfk062 1:CAS:528:DC%2BD28XivVOntb8%3D 16431890
26. HS Thomsen P Marckmann VB Logager 2008 Update on nephrogenic systemic fibrosis Magn Reson Imaging Clin N Am 16 551 560 10.1016/j.mric.2008.07.011 18926421
27. T Frenzel P Lengsfeld H Schirmer J Hutter HJ Weinmann 2008 Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C Invest Radiol 43 817 828 1:CAS:528:DC%2BD1cXhtlGmtLzN 19002053